168 related articles for article (PubMed ID: 37108788)
1. Mutated Flt3Lg Provides Reduced Flt3 Recycling Compared to Wild-Type Flt3Lg and Retains the Specificity of Flt3Lg-Based CAR T-Cell Targeting in AML Models.
Maiorova V; Mollaev MD; Vikhreva P; Chudakov DM; Kibardin A; Maschan MA; Larin S
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108788
[TBL] [Abstract][Full Text] [Related]
2. Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells.
Wang Y; Xu Y; Li S; Liu J; Xing Y; Xing H; Tian Z; Tang K; Rao Q; Wang M; Wang J
J Hematol Oncol; 2018 May; 11(1):60. PubMed ID: 29716633
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery.
Sommer C; Cheng HY; Nguyen D; Dettling D; Yeung YA; Sutton J; Hamze M; Valton J; Smith J; Djuretic I; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2020 Oct; 28(10):2237-2251. PubMed ID: 32592688
[TBL] [Abstract][Full Text] [Related]
4. CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations.
Tang L; Huang H; Tang Y; Li Q; Wang J; Li D; Zhong Z; Zou P; You Y; Cao Y; Kong Y; Guo A; Zhou S; Li H; Meng F; Xiao Y; Zhu X
Clin Transl Med; 2022 Sep; 12(9):e1043. PubMed ID: 36163632
[TBL] [Abstract][Full Text] [Related]
5. Natural Flt3Lg-Based Chimeric Antigen Receptor (Flt3-CAR) T Cells Successfully Target Flt3 on AML Cell Lines.
Maiorova V; Mollaev MD; Vikhreva P; Kulakovskaya E; Pershin D; Chudakov DM; Kibardin A; Maschan MA; Larin S
Vaccines (Basel); 2021 Oct; 9(11):. PubMed ID: 34835169
[TBL] [Abstract][Full Text] [Related]
6. Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against
Niswander LM; Graff ZT; Chien CD; Chukinas JA; Meadows CA; Leach LC; Loftus JP; Kohler ME; Tasian SK; Fry TJ
Haematologica; 2023 Feb; 108(2):457-471. PubMed ID: 35950535
[TBL] [Abstract][Full Text] [Related]
7. CAR T-cells targeting FLT3 have potent activity against FLT3
Jetani H; Garcia-Cadenas I; Nerreter T; Thomas S; Rydzek J; Meijide JB; Bonig H; Herr W; Sierra J; Einsele H; Hudecek M
Leukemia; 2018 May; 32(5):1168-1179. PubMed ID: 29472720
[TBL] [Abstract][Full Text] [Related]
8. Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center.
Willis C; Menon J; Unni S; Au T; Yoo M; Biskupiak J; Brixner D; Ndife B; Joseph G; Bonifacio G; Stein E; Tantravahi S; Shami PJ; Kovacsovics T; Stenehjem D
Leuk Res; 2019 Dec; 87():106262. PubMed ID: 31756575
[TBL] [Abstract][Full Text] [Related]
9. Targeting FLT3-specific chimeric antigen receptor T cells for acute lymphoblastic leukemia with KMT2A rearrangement.
Suematsu M; Yagyu S; Yoshida H; Osone S; Nakazawa Y; Sugita K; Imamura T; Iehara T
Cancer Immunol Immunother; 2023 Apr; 72(4):957-968. PubMed ID: 36214866
[TBL] [Abstract][Full Text] [Related]
10. A novel approach for relapsed/refractory FLT3
Li KX; Wu HY; Pan WY; Guo MQ; Qiu DZ; He YJ; Li YH; Yang DH; Huang YX
Mol Cancer; 2022 Mar; 21(1):66. PubMed ID: 35246156
[TBL] [Abstract][Full Text] [Related]
11. Off-the-shelf CAR-engineered natural killer cells targeting FLT3 enhance killing of acute myeloid leukemia.
Mansour AG; Teng KY; Li Z; Zhu Z; Chen H; Tian L; Ali A; Zhang J; Lu T; Ma S; Lin CM; Caligiuri MA; Yu J
Blood Adv; 2023 Oct; 7(20):6225-6239. PubMed ID: 37379267
[TBL] [Abstract][Full Text] [Related]
12. Evolution and Potential Subfunctionalization of Duplicated
Paiola M; Ma S; Robert J
J Immunol; 2022 Sep; 209(5):960-969. PubMed ID: 36130129
[TBL] [Abstract][Full Text] [Related]
13. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
Oelsner S; Waldmann A; Billmeier A; Röder J; Lindner A; Ullrich E; Marschalek R; Dotti G; Jung G; Große-Hovest L; Oberoi P; Bader P; Wels WS
Int J Cancer; 2019 Oct; 145(7):1935-1945. PubMed ID: 30860598
[TBL] [Abstract][Full Text] [Related]
14. Nonclinical Safety Assessment of AMG 553, an Investigational Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Acute Myeloid Leukemia.
Karbowski C; Goldstein R; Frank B; Kim K; Li CM; Homann O; Hensley K; Brooks B; Wang X; Yan Q; Hernandez R; Adams G; Boyle M; Arvedson T; Lebrec H
Toxicol Sci; 2020 Sep; 177(1):94-107. PubMed ID: 32589753
[TBL] [Abstract][Full Text] [Related]
15. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
Front Immunol; 2020; 11():580328. PubMed ID: 33384686
[TBL] [Abstract][Full Text] [Related]
16. A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo.
Giannakopoulou E; Lehander M; Virding Culleton S; Yang W; Li Y; Karpanen T; Yoshizato T; Rustad EH; Nielsen MM; Bollineni RC; Tran TT; Delic-Sarac M; Gjerdingen TJ; Douvlataniotis K; Laos M; Ali M; Hillen A; Mazzi S; Chin DWL; Mehta A; Holm JS; Bentzen AK; Bill M; Griffioen M; Gedde-Dahl T; Lehmann S; Jacobsen SEW; Woll PS; Olweus J
Nat Cancer; 2023 Oct; 4(10):1474-1490. PubMed ID: 37783807
[TBL] [Abstract][Full Text] [Related]
17. Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance.
Staudt D; Murray HC; McLachlan T; Alvaro F; Enjeti AK; Verrills NM; Dun MD
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30332834
[TBL] [Abstract][Full Text] [Related]
18. Phosphoproteome analyses reveal specific implications of Hcls1, p21-activated kinase 1 and Ezrin in proliferation of a myeloid progenitor cell line downstream of wild-type and ITD mutant Fms-like tyrosine kinase 3 receptors.
Habif G; Grasset MF; Kieffer-Jaquinod S; Kuhn L; Mouchiroud G; Gobert-Gosse S
J Proteomics; 2013 Jan; 78():231-44. PubMed ID: 23017497
[TBL] [Abstract][Full Text] [Related]
19. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.
Zheng R; Levis M; Piloto O; Brown P; Baldwin BR; Gorin NC; Beran M; Zhu Z; Ludwig D; Hicklin D; Witte L; Li Y; Small D
Blood; 2004 Jan; 103(1):267-74. PubMed ID: 12969963
[TBL] [Abstract][Full Text] [Related]
20. Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia.
Hu X; Chen F
Hematology; 2019 Dec; 24(1):651-660. PubMed ID: 31533545
[No Abstract] [Full Text] [Related]
[Next] [New Search]
